国际医学
(000516)
| 流通市值：96.33亿 | | | 总市值：98.29亿 |
| 流通股本：21.94亿 | | | 总股本：22.39亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 969,398,246.51 | 4,074,514,927.55 | 2,995,437,323.47 | 2,034,307,690.46 |
| 营业收入 | 969,398,246.51 | 4,074,514,927.55 | 2,995,437,323.47 | 2,034,307,690.46 |
| 二、营业总成本 | 1,046,750,589.27 | 4,523,904,141.74 | 3,379,382,067.18 | 2,279,057,237.69 |
| 营业成本 | 872,855,125.02 | 3,738,107,201.41 | 2,798,056,817.36 | 1,875,680,998.18 |
| 税金及附加 | 16,088,961.73 | 64,091,229.67 | 48,105,083.71 | 31,930,143.98 |
| 销售费用 | 9,604,118.67 | 51,631,020.09 | 33,971,286.35 | 12,906,646.69 |
| 管理费用 | 114,577,252.8 | 518,380,015.19 | 382,019,497.6 | 276,375,329.41 |
| 研发费用 | 2,167,282.07 | 7,631,106.66 | 6,045,483.1 | 3,933,910.53 |
| 财务费用 | 31,457,848.98 | 144,063,568.72 | 111,183,899.06 | 78,230,208.9 |
| 其中:利息费用 | 29,800,822.3 | 137,887,134.4 | 108,057,891.1 | 74,534,722.28 |
| 其中:利息收入 | 366,477.46 | 3,842,828.85 | 4,617,577.08 | 1,799,808.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -2,042,823.37 | -5,975,852.8 | -6,588,458.25 | 2,320,448.33 |
| 加:投资收益 | 3,682,862.76 | 33,957,393.43 | 20,758,603.91 | 20,940,436.87 |
| 资产处置收益 | - | 177,685.46 | - | - |
| 资产减值损失(新) | -639,259.84 | -2,398,127.54 | - | - |
| 信用减值损失(新) | 2,385,181.72 | 18,006,938.39 | 5,990,098.91 | 7,608,278.07 |
| 其他收益 | 2,802,550.49 | 5,181,657.94 | 3,282,298.92 | 2,217,058.32 |
| 四、营业利润 | -71,163,831 | -400,439,519.31 | -360,502,200.22 | -211,663,325.64 |
| 加:营业外收入 | 41,889.47 | 690,303.46 | 672,711.27 | 571,131.57 |
| 减:营业外支出 | 5,300 | 548,479.5 | 381,388.26 | 2,039,546.9 |
| 五、利润总额 | -71,127,241.53 | -400,297,695.35 | -360,210,877.21 | -213,131,740.97 |
| 减:所得税费用 | 2,544,638.37 | 20,729,444.68 | 13,818,238.76 | 5,181,229.26 |
| 六、净利润 | -73,671,879.9 | -421,027,140.03 | -374,029,115.97 | -218,312,970.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -73,671,879.9 | -421,027,140.03 | -374,029,115.97 | -218,312,970.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -48,341,549.48 | -313,075,395.65 | -293,656,543.41 | -164,961,830.49 |
| 少数股东损益 | -25,330,330.42 | -107,951,744.38 | -80,372,572.56 | -53,351,139.74 |
| 扣除非经常损益后的净利润 | -52,310,106.74 | -344,803,924.12 | -311,612,660.98 | -189,033,816.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.14 | -0.13 | -0.07 |
| (二)稀释每股收益 | -0.02 | -0.14 | -0.13 | -0.07 |
| 九、综合收益总额 | -73,671,879.9 | -421,027,140.03 | -374,029,115.97 | -218,312,970.23 |
| 归属于母公司股东的综合收益总额 | -48,341,549.48 | -313,075,395.65 | -293,656,543.41 | -164,961,830.49 |
| 归属于少数股东的综合收益总额 | -25,330,330.42 | -107,951,744.38 | -80,372,572.56 | -53,351,139.74 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |